Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Shares Outstanding (2022 - 2025)

Historic Shares Outstanding for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $113.2 million.

  • NewAmsterdam Pharma's Shares Outstanding rose 2279.28% to $113.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 2279.28%. This contributed to the annual value of $108.1 million for FY2024, which is 3103.51% up from last year.
  • Latest data reveals that NewAmsterdam Pharma reported Shares Outstanding of $113.2 million as of Q3 2025, which was up 2279.28% from $112.5 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma's Shares Outstanding peaked at $113.2 million during Q3 2025, and registered a low of $81.8 million during Q1 2023.
  • Moreover, its 4-year median value for Shares Outstanding was $89.9 million (2024), whereas its average is $94.2 million.
  • Per our database at Business Quant, NewAmsterdam Pharma's Shares Outstanding tumbled by 89.1% in 2023 and then skyrocketed by 3103.51% in 2024.
  • Over the past 4 years, NewAmsterdam Pharma's Shares Outstanding (Quarter) stood at $83.2 million in 2022, then decreased by 0.89% to $82.5 million in 2023, then surged by 31.04% to $108.1 million in 2024, then increased by 4.73% to $113.2 million in 2025.
  • Its Shares Outstanding stands at $113.2 million for Q3 2025, versus $112.5 million for Q2 2025 and $112.2 million for Q1 2025.